Meticulous Research® has released a comprehensive report on the cancer/tumor profiling market, forecasting its growth to $24.70 billion by 2031, with a robust CAGR of 10.9% over the forecast period. This growth is driven by several factors, including the rising prevalence of cancer, increased pharmaceutical R&D investments, the expansion of targeted therapies, and the discovery of new actionable biomarkers. Advancements in multi-omics tumor profiling and declining costs of next-generation sequencing (NGS) are also contributing to market expansion. However, challenges such as high capital investments for NGS setups and lengthy turnaround times are potential market constraints.
Market Segmentation
The cancer/tumor profiling market is segmented by:
Biomarker Type: Protein Biomarkers and Genetic BiomarkersTechnology: Next-Generation Sequencing (NGS), Polymerase Chain Reaction (PCR), In-situ Hybridization (ISH), Immunohistochemistry (IHC), and Other TechnologiesCancer Type: Breast Cancer, Colorectal Cancer, Lung Cancer, Prostate Cancer, Lymphoma, Leukemia, Cervical Cancer, and Other Cancer TypesApplication: Clinical Applications and Research ApplicationsEnd User: Pharmaceutical & Biopharmaceutical Companies, Hospitals & Diagnostic Laboratories, Academic & Research Institutes, and Contract Research Organizations (CROs)Download Free Research PDF @ https://www.meticulousresearch.com/download-sample-report/cp_id=5630
Key Insights:
Biomarker Type: Genetic biomarkers are projected to dominate, expected to hold a 72% market share in 2024. This dominance is due to their critical role in understanding cancer's molecular pathology and guiding treatment decisions.Technology: The NGS segment is anticipated to lead the market in 2024, driven by its high sensitivity, lower sequencing costs, and availability of cost-effective sequencers.Cancer Type: Breast cancer is forecasted to command the largest share of the market in 2024. This is fueled by an increase in breast cancer cases, supportive government initiatives, and rising healthcare expenditures.Application: Research applications are expected to lead the market in 2024 due to increased cancer incidence, demand for precision medicine, and advancements in profiling technologies like NGS and PCR.End User: Pharmaceutical & Biopharmaceutical Companies are predicted to hold the largest market share of 40.9% in 2024, owing to their active role in genomic research, precision medicine, and biomarker discovery.Geographic Insights:
In 2024, North America is projected to capture the largest market share of 42.7%, followed by Europe and Asia-Pacific. This dominance is attributed to North America's high cancer burden, significant R&D investments, and government support for cancer research.
Quick Buy – Cancer/Tumor Profiling Market - Global Opportunity Analysis and Industry Forecast (2024-2031), Research Report: https://www.meticulousresearch.com/Checkout/81920399
Key Players:
Notable companies in the cancer/tumor profiling market include Thermo Fisher Scientific Inc. (U.S.), Illumina, Inc. (U.S.), QIAGEN N.V. (Netherlands), F. Hoffmann-La Roche Ltd. (Switzerland), Agilent Technologies, Inc. (U.S.), NanoString Technologies, Inc. (U.S.), HTG Molecular Diagnostics, Inc. (U.S.), Agendia Inc. (U.S.), Personalis, Inc. (U.S.), Exact Sciences Corporation (U.S.), and Tempus Labs, Inc. (U.S.).
Contact Us:
Meticulous Research®
Email- [email protected]
Contact Sales- +1-646-781-8004
Connect with us on LinkedIn- https://www.linkedin.com/company/meticulous-research
Sign in to leave a comment.